Because IGFBP‐4 is a robust cardioprotective agent against cardiac ischaemic injury,4 combined therapy of IGFBP‐4 with other angiogenic factors may be a promising strategy for the treatment of MI. The gene discussed is IGFBP4; the disease is myocardial infarction.